Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Smyth

Showing results (31-40 of 379) with videos related to

Pageof 38
Sort By:
ESMO Open|November 2, 2019
Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancerMaria Alsina, Elizabeth C Smyth
JAMA Oncology|October 5, 2017
Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer-Is There Room for Improvement?Elizabeth C Smyth, David Cunningham
The Lancet. Gastroenterology & Hepatology|October 26, 2019
27 years of stomach cancer: painting a global pictureAngelica Petrillo, Elizabeth C Smyth
JAMA Oncology|September 4, 2020
Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?Elizabeth C Smyth, Markus Moehler
Cancer Cell|June 6, 2022
Combination immune checkpoint blockade in advanced untreated gastroesophageal adenocarcinoma: Seeking biomarkers for durable benefitElisa Fontana, Elizabeth C Smyth
Therapeutic Advances in Medical Oncology|September 7, 2019
Late-line treatment in metastatic gastric cancer: today and tomorrowElizabeth C Smyth, Markus Moehler
The Lancet. Oncology|October 5, 2019
Nivolumab for previously treated squamous oesophageal carcinomaElizabeth C Smyth, Florian Lordick
Annals of Translational Medicine|January 25, 2021
Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patientsMaria Alsina, Elizabeth C Smyth
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1970
Electron microscopic study of inhibition of macrophage migration in delayed hypersensitivityA C Smyth, L Weiss
Cancer Discovery|September 4, 2021
Dissecting Response and Resistance to Anti-PD-1 Therapy in Microsatellite-Unstable Gastric CancerElisa Fontana, Elizabeth C Smyth
Pageof 38

Showing results (31-40 of 379) with videos related to

Sort By:
Pageof 38
ESMO Open|November 2, 2019
Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancerMaria Alsina, Elizabeth C Smyth
JAMA Oncology|October 5, 2017
Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer-Is There Room for Improvement?Elizabeth C Smyth, David Cunningham
The Lancet. Gastroenterology & Hepatology|October 26, 2019
27 years of stomach cancer: painting a global pictureAngelica Petrillo, Elizabeth C Smyth
JAMA Oncology|September 4, 2020
Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?Elizabeth C Smyth, Markus Moehler
Cancer Cell|June 6, 2022
Combination immune checkpoint blockade in advanced untreated gastroesophageal adenocarcinoma: Seeking biomarkers for durable benefitElisa Fontana, Elizabeth C Smyth
Therapeutic Advances in Medical Oncology|September 7, 2019
Late-line treatment in metastatic gastric cancer: today and tomorrowElizabeth C Smyth, Markus Moehler
The Lancet. Oncology|October 5, 2019
Nivolumab for previously treated squamous oesophageal carcinomaElizabeth C Smyth, Florian Lordick
Annals of Translational Medicine|January 25, 2021
Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patientsMaria Alsina, Elizabeth C Smyth
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1970
Electron microscopic study of inhibition of macrophage migration in delayed hypersensitivityA C Smyth, L Weiss
Cancer Discovery|September 4, 2021
Dissecting Response and Resistance to Anti-PD-1 Therapy in Microsatellite-Unstable Gastric CancerElisa Fontana, Elizabeth C Smyth
Pageof 38